Lawyers and Settlements
What are you looking for?
Email to a friendEmail
Home Page >> Hot Legal Issues >> Bextra

Bextra and Stevens Johnson Syndrome

The anti-inflammatory drug Bextra is a pain management medication prescribed for patients suffering arthritis, needing acute pain management, or who suffer severe menstrual symptoms, and is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). Prescription NSAIDs, such as Bextra, are one of the leading classes of drugs that cause Stevens Johnson Syndrome (SJS).

FREE CASE EVALUATION

Send your claim to a Lawyer who will review your case at NO COST or obligation.Get Legal Help Now

Bextra Stevens Johnson Syndrome

Prescription pain relievers such as Bextra (valdecoxib) have been linked to Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN). Since its link to SJS beginning in 2004, numerous SJS Bextra lawsuits have been filed.

Stevens Johnson Syndrome is a rare inflammatory skin disorder that can be life-threatening. The disease causes lesions in the mouth, eyes and on the body. Stevens Johnson Syndrome can occur at any age. The majority of cases range between the ages of 20 and 40; one-fifth of the cases occured in people under the age of 20.

In some cases, permanent skin damage and scarring occur. Lesions on internal organs can cause serious inflammation of the lungs, heart and kidneys. Up to 27 percent of those affected by Stevens Johnson Syndrome or related illnesses incur long term eye damage or vision loss. Up to 15 percent of patients with this syndrome die from the condition.

In April 2005, the FDA asked Pfizer, the drug giant manufacturer, to remove Bextra from the market. In October 2008, Pfizer reached an $894 million deal to settle most lawsuits related to risk of heart attack and strokes over its withdrawn pain reliever Bextra.

Bextra and Stevens Johnson Syndrome in the News

APR-07-05: The FDA announces a U.S. recall of Bextra after analyzing that the risks are greater than the benefits to consumers. Bextra has also been banned in Canada and Europe. Celebrex, a drug similar to Bextra, is still on the market and still poses a risk to consumers. The FDA will work with the manufacturer to revise the warning label and include the risk of cardiovascular (CV) events and gastrointestinal (GI) bleeding.

DEC-09-04: The FDA increases warning of Bextra after receiving more reports of serious, potentially fatal, skin reactions such as SJS and TEN. Patients known to have an allergy to sulfa products should not take Bextra.

Bextra Stevens Johnson Syndrome Complaint

If you or a loved one has suffered from Stevens Johnson Syndrome as a side effect of taking Bextra, you may qualify for damages or remedies that may be awarded in a possible class action lawsuit. Please click the link below to submit your complaint to a lawyer who will review your case at no cost or obligation.



Last updated on Aug-30-11

ARTICLES AND INTERVIEWS

Bextra and Stevens Johnson Syndrome—FAQ
Bextra and Stevens Johnson Syndrome—FAQ Washington, DC: An association between Bextra and Stevens Johnson Syndrome has been known for a number of years, and because of that, many lawsuits have been filed against Pfizer, the maker of Bextra [READ MORE]

Bextra Link to Stevens-Johnson Syndrome a Serious Concern
Bextra Link to Stevens-Johnson Syndrome a Serious Concern Washington, DC: While the medication was withdrawn from the US market in 2005, Bextra's link to serious side effects such as Stevens-Johnson Syndrome remains a serious issue for the thousands of patients across the country who took the drug [READ MORE]

Potential Jet Lag Drug Linked to Stevens-Johnson Syndrome
Potential Jet Lag Drug Linked to Stevens-Johnson Syndrome Silver Spring, MD: A drug that can potentially fight jet lag has been linked to some rare, life-threatening skin rashes such as Stevens-Johnson Syndrome, NPR reports [READ MORE]

YOUR STORIES

Publish your experience here for our readers to learn from.


 
FAQ | TOS | Privacy | Disclaimer | About Us | Contact Us | Press | Advertise | Member Login | Site Map

This work is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License © 2001-2012 Online Legal Media. All rights reserved.